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Background: Differential processing of the amyloid precursor protein liberates either amyloid-ß, a causative agent
of Alzheimer’s disease, or secreted amyloid precursor protein-alpha (sAPPα), which promotes neuroprotection,
neurotrophism, neurogenesis and synaptic plasticity. The underlying molecular mechanisms recruited by sAPPα that
underpin these considerable cellular effects are not well elucidated. As these effects are enduring, we hypothesised
that regulation of gene expression may be of importance and examined temporally specific gene networks and
pathways induced by sAPPα in rat hippocampal organotypic slice cultures. Slices were exposed to 1 nM sAPPα or
phosphate buffered saline for 15 min, 2 h or 24 h and sAPPα-associated gene expression profiles were produced
for each time-point using Affymetrix Rat Gene 1.0 ST arrays (moderated t-test using Limma: p < 0.05, and fold
change ± 1.15).
Results: Treatment of organotypic hippocampal slice cultures with 1 nM sAPPα induced temporally distinct gene
expression profiles, including mRNA and microRNA associated with Alzheimer’s disease. Having demonstrated that
treatment with human recombinant sAPPα was protective against N-methyl D-aspartate-induced toxicity, we next
explored the sAPPα-induced gene expression profiles. Ingenuity Pathway Analysis predicted that short-term
exposure to sAPPα elicited a multi-level transcriptional response, including upregulation of immediate early gene
transcription factors (AP-1, Egr1), modulation of the chromatin environment, and apparent activation of the
constitutive transcription factors CREB and NF-κB. Importantly, dynamic regulation of NF-κB appears to be integral
to the transcriptional response across all time-points. In contrast, medium and long exposure to sAPPα resulted in
an overall downregulation of gene expression. While these results suggest commonality between sAPPα and our
previously reported analysis of plasticity-related gene expression, we found little crossover between these datasets.
The gene networks formed following medium and long exposure to sAPPα were associated with inflammatory
response, apoptosis, neurogenesis and cell survival; functions likely to be the basis of the neuroprotective effects of
sAPPα.
Conclusions: Our results demonstrate that sAPPα rapidly and persistently regulates gene expression in rat
hippocampus. This regulation is multi-level, temporally specific and is likely to underpin the neuroprotective effects
of sAPPα.
Keywords: Secreted amyloid precursor protein alpha, Hippocampus, Organotypic slice cultures, Microarray,
Ingenuity pathway analysis, Neuroprotection, Immediate early genes, MicroRNA, NF-κB* Correspondence: margaret.ryan@otago.ac.nz
1Brain Health Research Centre, University of Otago, PO Box 56, Dunedin
New Zealand
2Department of Anatomy, Otago School of Medical Sciences, PO Box 913,
Dunedin, New Zealand
Full list of author information is available at the end of the article
© 2013 Ryan et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the ord. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Ryan et al. BMC Genomics 2013, 14:376 Page 2 of 14
http://www.biomedcentral.com/1471-2164/14/376Background
Amyloid precursor protein (APP) is the parent molecule
of the neurotoxic amyloid-β, implicated in the aetiology
of Alzheimer’s disease. Amyloid-β is generated by
sequential cleavage of APP by β and γ-secretases. How-
ever, the likely predominant route of APP processing is
via α-secretase [1,2], which not only precludes amyloid-β
production but also generates secreted amyloid precursor
protein alpha (sAPPα) [3,4]. This molecule interacts with
the β-secretase, BACE1, and directly inhibits amyloid-β
production [5]. Furthermore, mounting evidence impli-
cates sAPPα in a wide variety of neuronal processes. It has
been shown to both protect against glutamate toxicity in
rat hippocampal neurons in vitro and in rat models of
traumatic brain injury in vivo [6,7] and promote neurite
outgrowth in vitro [8,9]. Furthermore, sAPPα has recently
been shown to not only direct human embryonic stem
cells into neuronal precursor cells [10,11], but to increase
proliferation of neural precursor cells from the rat hippo-
campus in vitro, and promote their proliferation in the
mouse hippocampus in vivo [12]. Additionally, sAPPα has
been shown to enhance synaptic plasticity and restore
memory deficits in rats and mice in vivo [13-16]. While a
definitive cognate receptor for sAPPα has not yet been
identified, sAPPα is known to activate intracellular signal-
ling cascades in both neurons and glia and enhance synap-
tic protein synthesis in vitro [17-21]. As the reported
physiological effects of sAPPα, are dependent on rapid
and persistent alterations in gene expression, it is also
likely that regulation of transcription is integral to the
function of sAPPα.
Recently, expression of the transcription factor Egr1 was
shown to mediate sAPPα stimulated axonal outgrowth of
primary neurons from mice in vitro [22], and sAPPα has
previously been shown to induce the expression of several
neuroprotective genes in mouse organotypic hippocampal
slices [23]. This observation is particularly important
as the hippocampus is a region vulnerable to the early
neurodegenerative changes observed in Alzheimer’s
disease. Interestingly, however, sAPPα knock-in mice
show significantly lower expression of the plasticity
related genes Arc, Egr2 and Fos. Furthermore, in
general, the gene expression profiles of APP knockout
and sAPPα knock-in mice do not differ substantially
[24], questioning the role of the N-terminal region of
APP in regulation of gene expression. In light of these
somewhat conflicting data we sought to determine
whether the application of sAPPα to organotypic
hippocampal slice cultures for up to 24 h alters gene
expression, and if so, whether the gene networks or
biological pathways identified reflected the known
physiological roles of sAPPα. We found that sAPPα
rapidly enhances the transcription environment and
alters subsequent gene expression in a manner that islikely to underpin the reported neuroprotective effects
of sAPPα.
Results
sAPPα protects against N-methyl D-aspartate toxicity
We have previously shown that purified human recom-
binant sAPPα produced in our laboratory [25] regulates
protein synthesis [17], synaptic plasticity and memory
[16], as well as neurogenesis [10]. However, prior to
determining the effects of sAPPα on gene expression, we
sought to extend our assessment of the functionality of
recombinant sAPPα. Accordingly, we tested whether
sAPPα could protect against N-methyl-D-aspartate
(NMDA)-induced excitotoxicity in hippocampal organo-
typic slice cultures.
Hippocampal organotypic slice cultures (representative
slices, Figure 1A, B) were challenged with NMDA (30 μM,
30 min) and cell death was assessed by measurement of
propidium iodide (PI) fluorescence 48 h later. In phos-
phate buffered saline (PBS)-treated control cultures, the
tissue had low PI fluorescence across all hippocampal
regions, indicating little cell death (Figure 1C). In con-
trast, NMDA treatment caused significantly higher
levels of PI fluorescence in Cornu Ammonis area 1 and
3 (CA1, CA3) and the inner and outer blades of the
dentate gyrus (DG) relative to the PBS-treated control
cultures (p = 0.000001, 1-way ANOVA followed by a
Bonferroni post-hoc test; Figure 1D, F), indicating
induction of extensive cell death. Slices were incubated
with 0.03, 0.1, 1, 10 nM sAPPα or PBS-control for 24 h
prior to, and for 48 h following NMDA insult. Incuba-
tion with 1 nM sAPPα resulted in a significant reduc-
tion in PI fluorescence in CA1 (p = 0.033) and the inner
(p = 0.034) and outer blades (p = 0.0001) of the DG com-
pared with NMDA treatment alone (Figure 1E, F), indi-
cating a neuroprotective effect. No significant effects
were detected following incubation with the other
sAPPα + NMDA concentrations but sAPPα exposure
trended towards a U-shaped dose–response curve (see
Additional file 1: Figure S1). Together, these findings in-
dicate that 1 nM sAPPα increases cell survival following
NMDA exposure. Although sAPPα has previously been
shown to protect against glutamate toxicity [6], glutam-
ate and NMDA may induce excitotoxicity by non-
overlapping signaling pathways [26], and so this study
extends the known neuroprotective effects of sAPPα
and validates the activity of sAPPα in our model system.
Regulation of gene expression by sAPPα
To investigate the temporal effects of sAPPα on the hip-
pocampal transcriptome, hippocampal organotypic slice
cultures were treated with 1 nM sAPPα (the optimally
neuroprotective concentration) or PBS for either 15 min,
2 h or 24 h and expression profiling was performed with
Figure 1 sAPPα protects organotypic hippocampal slices from excitotoxic cell death. (A) Representative brightfield image of a rat
organotypic hippocampal slice. (B) Composite hippocampal slice showing high PI fluorescence, associated with total cell death in CA1 and CA3
and the dentate gyrus (DG) inner (ib) and outer blades (ob). Total cell death was induced by maintaining the slice at room temperature for 24 h
in the absence of elevated CO2 levels. (C) Minimal PI fluorescence in the DG of a PBS-treated control slice. (D) Widespread PI fluorescence in the
DG 48 h after NMDA challenge. (E) Reduced PI fluorescence in the DG following treatment with sAPPα and NMDA. (F) Regional analysis of PI
fluorescence in organotypic hippocampal slices. Fold change: NMDA or NMDA + sAPPα PI fluorescence relative to PBS-treated control. NMDA
treatment resulted in a >2 fold increase in PI fluorescence across all regions compared to PBS-control treated slices. Co-incubation with sAPPα
and NMDA significantly reduced PI fluorescence in the CA1, DG/ib and DG/ob compared to NMDA alone. 1-way ANOVA with a Bonferroni post-
hoc test: *p < 0.05, **p < 0.01, n = 4 animals, 19 slices/group.
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Data analysis, using dual selection criteria (moderated
t-test, p < 0.05 (Limma) and fold change ± 1.15), identified
temporally distinct sAPPα-induced patterns of expression
(Figure 2A), a subset of which was confirmed by quanti-
tative PCR (qPCR; Figure 3 and see Additional file 2:Figure 2 sAPPα regulates gene expression in a temporally specific m
differentially expressed following exposure of organotypic hippocampal slic
were downregulated at 2 h and 24 h. Differentially expressed genes were i
see text for further details. (B) Venn diagram showing that the three dataseTables S1-S4). The majority of genes were modestly
changed (fold change: -2.9 to 3.2), an effect particular to
neurobiological tissue [27] and consistent with previous
studies [24,28-30]. Interestingly, two thirds (66%) of
differentially expressed genes were upregulated in the
15 min dataset, while the majority of differentiallyanner. (A) Histogram showing that the majority of genes identified as
e cultures to sAPPα were upregulated at 15 min, while the majority
dentified using a dual selection criteria (±1.15 fold change; p < 0.05),
ts involved distinct gene sets.
Figure 3 Validation of selected differentially expressed genes
by qPCR. Microarray and corresponding qPCR results for (A) 15 min
(B) 2 h (C) 24 h. Results are expressed as mean fold change +/− SEM
and normalised to the housekeeping genes HPRT or PPIA using the
2-ΔΔCT method; n = 5 per group. Significance was assessed using 1
tailed Student’s t-tests: * p < 0.05.
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24 h (79%) (Figure 2A), suggesting that there is a relatively
rapid onset homeostatic control of gene expression. Over-
all, these data confirm that sAPPα, the N-terminal region
of APP, regulates gene expression in a time-dependent
manner.
To explore further how the effects of sAPPα on gene
expression changed with time, the expression profiles were
examined using aVenn diagram. This analysis showed that
the three datasets were largely distinct (Figure 2B; See
Additional file 3: Table S5). Only two genes were in com-
mon across all three datasets and only one was annotated.
Interestingly, this gene, acyl-protein thioesterase 2, (Apt2)showed a distinct temporal response to sAPPα treatment,
decreasing in expression at 15 min (−1.25 fold), increasing
at 2 h (+1.4 fold) and decreased by 24 h (−1.8 fold). Acti-
vation of APT2 results in depalmitoylation of substrate
proteins, a process important in regulating subcellular
localisation of plasticity related ion channels and GAP43
[31,32]. Thus, these data predict that regulation of Apt2
contributes to the plasticity-related effects of sAPPα.
As sAPPα enhances synaptic plasticity and restores
memory deficits [13-16], we next investigated whether
there was a significant crossover between our sAPPα-
regulated datasets and those regulated by synaptic plasti-
city. Previously, we identified distinct patterns of gene
expression elicited by hippocampal long-term potentiation
(LTP), a widely accepted model of memory mechanisms
and synaptic plasticity [29,30]. Here, we show that there
was little intersection between the genes within the
datasets (Table 1). For example, there were only five
rapidly responding genes in common across the early
time-points analysed (Table 1) and the fold change in
these overlapping genes was relatively curtailed in the
sAPPα dataset (Table 1). Despite this, when we com-
pared biological functions and pathways between the
two data sets, we found that they contained overlapping
functions related to Gene Expression (20 min LTP and
15 min sAPPα), Development (20 min LTP and 24 h
sAPPα) and Neurogenesis (5 h LTP and 24 h sAPPα).
This suggests that while there was little overlap in the
actual genes regulated, there is overlap in some of the
biological functions controlled by sAPPα and LTP.
As we found that sAPPα-induced a rapid upregulation
followed by a generalised downregulation of gene ex-
pression, we hypothesised that this temporal pattern
may be regulated by microRNA. A subset of probes on
the Affymetrix Rat Gene 1.0 ST arrays represent stem
loop microRNA sequences and therefore allow analysis
of primary and precursor microRNA. We found evi-
dence for regulation of 14 microRNA in response to
sAPPα (Table 2), the majority of which were upregulated
at 15 min, suggesting that the mature microRNA may
contribute to the later observed downregulation of gene
expression. In accordance with this, we found no evidence
for regulation by microRNA within the 15 min dataset
using the web application miRvestigator Framework [33].
However, analysis of the 2 h dataset identified miR-154
(p = 4.7e-04) as a candidate microRNA controlling the
expression of a subset of mRNA (Table 3). As the
miR-154 primary transcript was increased at 15 min
(Table 2) this suggests a role for miR-154 in sAPPα-
mediated gene expression, via mRNA degradation.
Furthermore, miRvestigator predicted regulation by
miR-201* (p = 2.4e-04) within the 24 h dataset (Table 3),
although we found no evidence for altered levels of the
primary microRNA transcript in our analyses.









Dusp1 Dual specificity phosphatase 1 1.2 3.9
Egr1 Early growth response 1 1.2 4.2
JunB Jun B proto-oncogene 1.2 6.6
Rbp3 retinol binding protein 3, interstitial 1.2 1.2

















Elov6 ELOVL family member 6,
elongation of long chain fatty acids
1.3 −1.3
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amyloid-ß and sAPPα are mutually exclusive, we analysed
how Alzheimer’s disease-associated genes were affected in
our three data sets. To achieve this we compared our
datasets with the Alzheimer gene database, AlzGene [34]
and carried out an in-depth literature search. We iden-
tified a group of mRNA and microRNA previouslyTable 2 Temporally specific regulation of microRNA by
sAPPα
MicroRNA Fold change
15 min 2 h 24 h
mir-9 1.3 −1.2 -
mir-27 1.2 - -
mir-29 1.3 - -
mir-30 1.2 - -
mir-130 1.2 - -
mir-135 1.3 - -
mir-154 1.2 - -
mir-204 - - −1.7
mir-218 1.2 - -
mir-219 - 1.2 -
mir-299 1.2 - -
mir-505 - 1.2 -
mir-544 1.2 - -
mir-592 1.2 - -associated with amyloid-ß induced toxicity (e.g. Frp2
and Ppif), or implicated in Alzheimer’s disease processes,
(miR-29 and miR-9) [35-47], (Table 4). As the expression
of these genes was opposite to that observed in
Alzheimer’s disease this analysis suggests that sAPPα may
act, in part, through the same pathways as amyloid-ß.sAPPα rapidly regulates transcriptional processes
To systematically investigate the functional significance
of the genes rapidly regulated by sAPPα, we used the
Ingenuity Pathway Analysis (IPA) software to identify
gene networks from the 15 min dataset. Gene expression
was identified as the most significant biological function
of the highest scoring network, with the majority of the
genes in this network upregulated (Figure 4A; score 34).
Analysis of this network showed multiple mechanisms
engaged by sAPPα to upregulate gene expression. This
includes inducible transcription factors of the AP-1 com-
plex [48] (FOS, JUNB and JUND) and the early growth re-
sponse transcription factor, EGR1. Enhanced expression of
Fos and Egr1 was confirmed by qPCR (Figure 3; Additional
file 2: Table S4.); furthermore, the upstream regulatory
analysis tool within IPA predicted downregulation of a
negative regulator of AP-1 activity Fosl1/Fra1 (FOS-like
antigen 1) [49,50], an effect likely to further amplify the
sAPPα-induced transcriptional response (Figure 5A).
This network also predicts that sAPPα mediates tran-
scription via activation of the plasticity-related transcrip-
tion factors, cAMP response element binding protein
(CREB) and nuclear factor kappa B (NF-κB), that form
central hubs within the network. While their expression
levels remain unchanged, this is highly consistent with
their roles as constitutive transcription factors regulated
by post-transcriptional modification. Indeed, this network
includes Dusp1 (+1.2 fold), a plasticity-related phosphatase
and Map3k14 (+1.2 fold), a kinase known to phosphoryl-
ate and activate NF-κB, as well as the NF-κB regulatory
molecule, Nf-κbid (+1.2 fold) [51,52]. Together these data
suggest that sAPPα treatment not only enhances the levels
of transcription factors but also contributes to a dynamic
interplay between a subset of protein kinases and phos-
phatases likely to maintain transcriptional activity.
Regulation of the chromatin environment is a third
predicted mechanism by which sAPPα regulates expres-
sion of genes in this network. The network contains
mediators of chromatin condensation (Kat2b: K(lysine)
acetyltransferase; +1.2 fold) and histone biotinylation
(Hlcs: holocarboxylase synthetase (biotin-(proprionyl-
CoA-carboxylase (ATP-hydrolysing)) ligase; +1.2 fold)
[53,54]. Upregulation of KAT2B is likely to result in re-
duced condensation of chromatin, occurring via acetylation
of TNP2 (nuclear transition protein 2) a molecule also
regulated within this network.
Table 3 Predicted microRNA-regulated genes following miRvestigator Framework Analysis
Predicted miR-154 regulated genes Gene title Transcript cluster ID Fold change P. Value
Cks2 CDC28 protein kinase regulatory subunit 2 10797559 −1.18 2.11E-02
Crygd Crystallin, gamma D 10928549 −1.17 4.33E-02
Dapp1 Dual adaptor of phosphotyrosine and 3-phosphoinositides 10826985 −1.18 5.54E-03
Hspa8 Heat shock 70kDa protein 8 10826604 −1.18 6.75E-03
Luzp1 Leucine zipper protein 1 10880685 1.15 3.83E-02
Olr1014 Olfactory receptor 1014 10893397 −1.17 5.47E-03
Olr1106 Olfactory receptor 1106 10906853 −1.17 4.04E-02
Olr1560 Olfactory receptor 1560 10750649 −1.20 3.44E-02
Olr1679 Olfactory receptor 1679 10830769 −1.15 3.47E-03
Olr75 Olfactory receptor 75 10709401 −1.19 2.45E-02
Olr862 Olfactory receptor 862 10879329 1.22 1.45E-02
Polr3G Polymerase (RNA) III (DNA directed) polypeptide G (32kD) 10718152 1.18 1.46E-02
Rgd1309139 Similar to CG5435-PA 10818370 −1.15 4.43E-02
Loc303448 Similar to glyceraldehyde-3-phosphate dehydrogenase 10715252 −1.15 3.41E-02
Slc5A7 Solute carrier family 5 (choline transporter), member 7 10921208 −1.19 2.23E-02
St18 Suppression of tumorigenicity 18 10875154 −1.21 1.98E-02
Predicted miR-201* regulated genes Gene title Transcript cluster ID Fold change P. value
Olr139 Olfactory receptor 139 10709469 −1.43 2.61E-02
Olr1532 Olfactory receptor 1532 10750614 −1.72 4.48E-02
Rpl36Al Ribosomal protein L36a-like 10829826 −1.36 4.34E-02
Rplp2 Ribosomal protein, large, P2 10762590 −1.43 3.70E-02
Rgd1307947 Similar to RIKEN cDNA C430008C19 10822064 −1.46 2.97E-02
Wwc2 WW and C2 domain containing 2 10788101 1.42 4.01E-02
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functional annotation tool, DAVID. This highlighted
Cognition and Sensory perception (Enrichment Score 2.2)
as well as Response to corticosterone (Enrichment Scores
1.77, 1.34) as significantly enriched functions (Additional
file 4: Table S6). Interestingly, there is an increase in basal
glucocorticoid levels in Alzheimer’s disease, [55,56]. Thus
sAPPα may regulate the expression of genes associated
with this pathway.
sAPPα-induced regulation of apoptosis and the
inflammatory response
We next explored the gene networks affected by exposure
to sAPPα for extended times. Following 2 h exposure to
sAPPα, Inflammatory Response was the most significant
biological function of the highest scoring network formed
used IPA (Figure 4B; score 26). This network contains the
proinflammatory cytokine Il1a, previously associated with
Alzheimer’s disease, development and plasticity [57-61],
immune associated genes (Cd80, Cr2, Cd27, Dapp1) and
chemokines (Ccl3, Ccl4, Ccl21). These chemokines are
involved in chemoattraction of immune cells to sites of
tissue damage but have widespread non-immunologicaleffects in the central nervous system, including regulation
of neural cell proliferation, migration, survival and synap-
tic transmission [62,63]. That sAPPα treatment promotes
regulation of chemokine responses is also supported from
analysis of the 2 h data set with the functional annotation
tool, DAVID (Additional file 4: Table S6).
Like the 15 min network, NF-κB forms a central hub
in this network, however, many of the genes contribut-
ing to the hub, including Ehf (ets homologous factor),
which promotes apoptosis [64], are downregulated.
Interestingly, using the upstream regulatory element
analysis tool to analyse the genes upregulated within
the 2 h dataset, it is predicted that sAPPα induces
inhibition of the transcription factor, tumour protein
53 (p53), which is also an important regulator of apop-
tosis, and is increased in Alzheimer’s disease [65,66]
(Figure 5B). In addition, upstream regulatory element
analysis using the entire 2 h dataset, predicts activation
of the transcription factors AP-1, HMGB1 (high mobil-
ity group box protein) and STAT3 (signal transducer
and activator of transcription 3) (Figure 5C) suggesting
other mechanisms by which sAPPα coordinates this
gene response.
Table 4 sAPPα regulates genes linked to amyloid-ß toxicity and Alzheimer’s disease
Gene symbol Gene title Fold change Functional effects References
15 min 2 h 24 h
Fish Adapter protein TKS5 1.2 - - Mediates the neurotoxic effect of amyloid-β [35]
Frp2 Formyl peptide receptor 2 - - −1.4 Activated by amyloid-β, may mediate inflammation




1.2 - −1.5 May interact with neurodegenerative disease-
associated proteins
[37]
Ppif Peptidylprolyl isomerase F - - −1.4 An absence of this gene is neuroprotective against
amyloid-β induced cell death
[38]
Tnf Tumour necrosis factor 1.4 - - Protects neurons against amyloid-β induced toxicity [39]
Ttr Transthyretin - −2.8 - Binds amyloid-β and prevents fibril formation in vitro [40]
Ccl-3 Chemokine (C-C motif) ligand 3 - 1.3 - Protein levels are increased in Alzheimer's disease [41]
Fos FBJ murine osteosarcoma viral
oncogene homolog
1.3 - - Gene expression is increased in Alzheimer's disease [42]
Ilib Interleulin 1-beta - 1.3 - Protein levels are increased in Alzheimer's disease [43]
MiR-9 MicroRNA- 9 1.2 −1.2 - Expression is reduced in Alzheimer's disease [44]
MiR-29 MicroRNA-29 1.3 - - Regulator of BACE1 and decreased in Alzheimer's
disease
[45]
Otc Ornithine transcarbamylase −1.2 - - Gene expression is increased in Alzheimer's disease [46]
Rgsl2 Regulator of G-protein signaling
like 2
- 1.2 - Gene associated with late onset Alzheimer's disease [47]
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inflammatory response and cell survival pathways
As the reported biological functions of sAPPα, such as
neuroprotection and regulation of memory, are endur-
ing physiological changes, we explored the gene expres-
sion response induced by a 24 h exposure to sAPPα. To
identify the functional relationships within the 24 h
differentially expressed gene list, we used the DAVID
functional annotation tool. This analysis identified
Neurogenesis, Morphogenesis and Development as im-
portant biological functions affected 24 h post-sAPPα
treatment (Enrichment Scores 2.26-1.48) (Additional
file 4: Table S6, See Additional file 5: Figure S2).
We extended analysis of this dataset by interpretation of
the highest scoring network derived using IPA, (Figure 4C).
This network was composed of genes with overlapping
biological functions, including upregulated genes related
to cell proliferation (Cd80, Ubn1, Ptprr; validated by
qPCR; Figure 3; Additional file 2: Table S4), regulation of
genes likely to promote cell survival (Inkb1, Cd80, Sgk1,
Fpr2, Cxcr4) and inhibit apoptosis (Gzmb; validated by
qPCR; Figure 3; Cxcr4, Ifnb1, Sgk1). As sAPPα has
previously been shown to promote growth, survival and
proliferation in neurons and stem cells [10,67,68] these
findings supports a role for sAPPα-induced gene ex-
pression in mediating these events.
Discussion
In order to better understand the role that regulation of
gene expression may play in mediating the wide-rangingcellular effects of sAPPα, we performed a global transcrip-
tome analysis in organotypic hippocampal slice cultures
treated with 1 nM sAPPα for 15 min, 2 h or 24 h. We
focused on the hippocampus as this region is essential
to learning and memory and is especially vulnerable to
degeneration in Alzheimer’s disease [69]. Our analysis
demonstrated that sAPPα rapidly regulates gene expres-
sion by engaging multiple transcriptional regulatory
mechanisms. This is evidenced by rapid and transient
upregulation of inducible transcription factors (AP-1 com-
plex, EGR1), temporally specific regulation of constitu-
tively expressed transcription factors (NF-κB, CREB) and
microRNA, as well as, modulation of the chromatin
environment.
Network analysis showed that regulation of NF-κB is a
consistent theme across all three time-points investi-
gated. This supports previous work proposing that the
neuroprotective effects of sAPPα are mediated through
activation of NF-κB and subsequent enhanced activation
of gene expression [70,71]. sAPPα-induced NF-κB acti-
vation is implicated in protecting neural cells from apop-
tosis, therefore our results suggest a role for specifically
regulated genes in this process [72]. Interestingly, NF-κB
has recently been intimately linked with amyloid-ß pro-
duction [73,74] and sAPPα modulates APP processing
[5]. Therefore, the control of amyloid-β production may
be crucially dependent on the activation status of NF-κB,
over which sAPPα has influence [70-72].
Increasing evidence points to the involvement of
dysregulated microRNA in Alzheimer’s disease [75] and
Figure 4 IPA network analysis of temporally-specific sAPPα-regulated datasets. (A) The highest scoring “direct” interaction network
(Score = 34) derived following 15 min exposure to sAPPα. (B) The highest scoring “all interactions” network (Score = 26) derived following 2 h
exposure to sAPPα. (C) The highest scoring “all interactions” network (Score = 35) derived following 24 h exposure to sAPPα. Red: upregulated
genes. Green: downregulated genes. White open nodes: genes not identified as differentially expressed but predicted to interact with sAPPα-
regulated genes by IPA. A solid line denotes a direct functional interaction of the products of the two genes. A dotted line denotes an indirect
interaction. An arrow indicates that a gene product “acts on” a target.
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in modulating the inflammatory circuit in Alzheimer’s
disease [76]. Our results highlight a role for microRNA
in sAPPα-induced regulation of gene expression. We
found that a short-term exposure to sAPPα was associ-
ated with upregulation of a subset of microRNA. As
medium to long-term sAPPα exposure resulted in a
general decrease in gene expression, we propose that
this may be mediated by microRNA. Interestingly, wereported a similar general effect on gene expression
following the induction of LTP, which we have shown
to be associated with altered levels of mature
microRNA [30]. Our results also demonstrate that
sAPPα induces a subset of plasticity-associated imme-
diate early genes, however, we found little evidence
that the sAPPα-induced gene response paralleled that
of the LTP gene response. Therefore, post-translational
modifications, and altered synaptic protein synthesis,
Figure 5 IPA transcription factor analysis. Each coloured node
represents a gene; Red: upregulated genes. Green: downregulated
genes. White open nodes represent Transcription factors. A solid line
denotes a direct functional interaction of the transcription factor on
the genes. A dotted line denotes an indirect interaction. (A) 15 min
upstream analysis results (B) 2 h upstream analysis results (C) 24 h,
upstream analysis results, up-regulated genes only.
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LTP [17,77,78].
It is of particular note that prolonged exposure to
sAPPα resulted in persistent effects on gene expression
that correlate closely with the documented neuro-
protective and neurogenic roles of sAPPα. This interpret-
ation is consistent with the only other microarray analysis
of sAPPα-regulated gene expression in the hippocampus
[23]. This study reported that treatment of mouse
organotypic slices with 1 nM sAPPα for 24 h also
resulted in regulation of several neuroprotective genes.
Interestingly, there was little coherence between the
genes identified in this study and our own. This may re-
sult from differences in the array type used (Affymetrix
MG-U74Av2 vs. Rat Gene 1.0 ST), the number of anno-
tated genes investigated (~9, 000 vs ~28, 000), the statis-
tical analyses performed (Wilcoxon signed rank test vs.
moderate paired t-test) or species (mouse vs. rat).
While there is a paucity of data estimating the physio-
logical levels of sAPPα, it has been estimated to fall
within the pM range within plasma and brain homoge-
nates [79-81], however, it is difficult to extrapolate these
concentrations to the ex vivo model used in this study.
Our studies highlight that 1 nM sAPPα is sufficient to
modulate gene expression in ex vivo models and em-
phasizes that both medium and longer-term exposure
to sAPPα elicits an inflammatory and immune gene re-
sponse, which likely provides a neuroprotective envir-
onment. This neuroprotective setting appears to be
strengthened by a parallel downregulation of apoptotic
pathways and increases in cell proliferation and survival.
Furthermore, we found evidence for the regulation of
genes associated with neurogenesis. Recent evidence
has also linked sAPPα with the induction of neurogen-
esis in the mammalian brain [10-12,82]. As new brain
cells have the capacity to integrate into previously
established neural networks and contribute to hippocam-
pal functioning [83], neurogenesis may also contribute to
the sAPPα-induced neuroprotective and memory enhan-
cing effects over the long-term.
Conclusion
In summary, our analyses consolidate the concept that
sAPPα regulates gene expression. We provide evidence
that this occurs in a temporally specific manner, and
occurs through providing an environment conducive for
transcription that results in activation of immediate
early gene transcription factors, known to mediate
neuroprotection and proliferation [84,85], and regula-
tion of microRNA. Furthermore, we demonstrate that
gene networks constructed following medium and
prolonged exposure to sAPPα reveal novel mechanisms
likely to underpin and consolidate the neuroprotective
stimulus induced by sAPPα in the hippocampus.
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Organotypic hippocampal slice cultures
Preparation and maintenance
Organotypic hippocampal slice cultures were prepared
from 7–10 day old Sprague Dawley rat pups of either
sex according to the method of Stoppini et al., [86]. The
animals were deeply anaesthetized with ketamine (100
mg/kg, i.p.), using a protocol approved by the University
of Otago Animal Ethics Committee to ensure minimal
animal suffering. Brains were removed and placed in
ice-cold filter-sterilized dissection media consisting of
Minimum Essential Medium (MEM) containing Hank’s
salts (95.5%, Gibco), penicillin-streptomycin solution
(1%, Gibco), HEPES buffer solution (2.5%, Gibco) and
1M Tris–HCl (1%, Invitrogen, CA, USA). Hippocampi
were then dissected free on an ice-cold glass plate and
transverse slices cut at 400 μm on a Mcllwain tissue
chopper (Mickle Laboratory Engineering, Surry, England).
Separated slices were individually placed onto cell culture
inserts (Millicell®, Millipore, MA, USA) held in 35 mm
disposable petri dishes (Nunc, Denmark). To control for
any gender differences, individual slices were randomised
across all inserts. Slices were subsequently incubated in
media containing MEM with Hank’s salts (50%), Hank’s
balanced salt solution (25%, Gibco) and heat-inactivated
horse serum (25%, Gibco) with 100 units of penicillin-
streptomycin/ml and buffered to pH 7.2 with 1 M HEPES
solution for three days at 37°C in a humidified incubator
containing 5% CO2, and subsequently at 34°C. Culture
medium was changed after the initial 24 h, and then every
3 days.
Experimental manipulation
Slices were allocated to experimental groups after 10–11
days in vitro (DIV). Neuroprotection assays and gene
expression experiments contained slices from 4 animals,
with 4–5 slices on each insert. All treatments were
conducted in culture medium in which the horse serum
was replaced with the same volume of MEM. Recombin-
ant human sAPPα was produced using human embryonic
kidney-293 cells in which the sAPPα gene fragment was
stably integrated [23].
Neuroprotection assay
Organotypic hippocampal slices were pre-treated with
sAPPα (0.03-10 nM) or PBS for 24 h before treatment
with NMDA (30 μM, 30 min) to induce partial,
hippocampal-wide neuronal cell death. sAPPα was re-
moved during the NMDA challenge, but subsequently
reintroduced at the same concentration for a further 48 h.
Fluorescence imaging
Levels of cell death were determined 48 h after NMDA
treatment using fluorescence imaging. Dead cells werelabelled using the fluorescent dye propidium iodide (PI,
ex. 536 nm, em. 617 nm). Emitted fluorescence was
imaged with a Zeiss Axio Scope A1 microscope fitted
with an LED illumination system and fluorescence filter
cube (LED module ex. 540–580 nm; Zeiss filter set 43,
ex. 545 nm- excitation, 605 nm-emission). Images were
acquired with a Scion Corporation (Frederick, MD, USA)
12-bit colour camera (model CFW-1612C) and Scion
Corporation VisiCapture image acquisition software. This
software enabled us to reduce electronic and background
image noise by collecting images that were the average of
the previous five frames. For the purposes of analysis, each
cultured slice was divided up into four principal areas
CA1, CA3, inner blade of the dentate gurus (DG/ib), and
outer blade of the dentate gyrus (DG/ob).
Image analysis
Cell death was quantified by measuring the average pixel
intensity within a manually-selected region-of-interest
(ROI) using ImageJ software (http://rsbweb.nih.gov/ij/
download.html). For each image, the cell body layer was
identified and manually selected as a ROI from which
the average pixel intensity was calculated. The positioning
of each ROI was dependent on the area to be analysed;
CA1: identified as the cell body layer immediately above
the DG; CA3: identified as the layer continuous with, and
extending beyond, CA1 and ending before it entered the
hilus of the DG. DG: divided into inner and outer blades
with an approximate mid-point selected to demarcate the
segments (Figure 1). The ROI size for each of the four
areas was kept consistent between images.
Data analysis
For assessment of regional sAPPα effects, raw PI intensity
values in the sAPPα groups were compared across the
control and NMDA group values using a 1-way ANOVA
with a post-hoc Bonferroni correction. Significance was
set at p < 0.05.
Transcriptome analysis
Organotypic hippocampal slices were incubated with
media containing 1 nM sAPPα or PBS for 15 min, 2 h or
24 h (n = 5 samples per treatment group, with each sam-
ple consisting of 5 randomly selected slices from 4 ani-
mals), rinsed with PBS, fixed in 70%(v/v) ETOH and
snap frozen. Total RNA was prepared from organotypic
hippocampal slices following tissue grinding on dry ice
and shearing through a 22G × 1" Ultra Thin Wall Needle
(Terumo®, Japan), using the NORGEN Total RNA Purifi-
cation Kit (Norgen Biotek Corporation, Canada), plus
DNAse I treatment step (Qiagen, Germany). RNA sam-
ple concentrations and integrity were determined using
spectrophotometry (Nanodrop 1000; Thermo Scientific,
USA) and a Bioanalyzer, using an RNA 6000 Nano
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Only samples with an average RNA integrity number >8
were used [87,88]. Array hybridizations were carried out
at the Otago Genomics Facility (University of Otago),
where RNA samples were biotin-labeled and hybridized
to Affymetrix Rat Gene 1.0 ST arrays. These arrays cover
27342 annotated genes represented by ~26 probes
spread across the full-length of each gene. A subset of
microRNA are represented on the Rat GeneChip. The
microRNA specific probes align to the stem loop se-
quences with the potential to identify both the primary
and precursor forms of the transcripts.
Microarray data analysis
The Robust Multichip Average (RMA) package was used
to normalize the data derived from treated and control
samples (Sketch expression consul, Affymetrix, USA). In
order to produce an inclusive list of sAPPα related genes
and microRNA suitable for network analysis, differen-
tially expressed genes were identified using two selection
criteria: a threshold fold change cutoff (± 1.15) and a
moderated t-test with a significance criterion of p < 0.05
[29]. The t-statistic was generated using the Limma
package, which utilizes a standard error moderated
across all genes using a simple Bayesian model and pro-
duces p-values with greater degrees of freedom and
hence greater reliability [89]. More stringent selection
criteria were not used in this study to avoid the risk of
Type 2 error and unnecessarily limit the datasets for net-
work analysis [90,91].
To investigate potential microRNA likely to regulate the
observed datasets, we used the web application miR-
vestigator Framework (http://mirvestigator.systemsbiology.
net/) that identifies microRNA responsible for co-regulated
gene expression patterns [33,92].Identification of biologically relevant networks and
biological functions
Ingenuity pathway analysis, version 9 (IPA) (Ingenuity®
Systems, www.ingenuity.com) was used to investigate
interaction-based relationships between the genes and
proteins encoded by the sAPPα-regulated gene expression
sets. The gene sets, containing Affymetrix identifiers and
corresponding expression values (p < 0.05), were submit-
ted for analysis and gene networks were produced. Each
network contains up to 35 genes and has an associated
score derived from a p-value, indicating the expected like-
lihood of the genes being present in a network compared
to that expected by chance. Scores of two or above have at
least a 99% likelihood of not being generated by chance.
As the use of multiple tools is highly recommended
for functional analysis of microarray data [93], we also
applied an alternative analysis approach, FunctionalAnnotation Clustering (DAVID [93]) to analyse the
differentially expressed genes. In contrast to IPA, which
is an interaction-based analysis, DAVID categorises the
genes into groups based on Gene Ontology terms, and
then displays similar annotations together. The total set of
genes on the appropriate microarray was used as the back-
ground. The annotation terms are clustered based on the
share of common genes and an EASE score, a modified
Fisher exact p-value, is produced for each annotation
term. Usually a p-value equal or smaller than 0.05 is con-
sidered strongly enriched in the annotation categories
[93]. Next, the annotation terms were clustered based
on similar annotation terms and genes. The overall
enrichment score of each cluster was based on the
EASE scores of each annotation term. Clusters with a
minimum enrichment score of 1.3 (equivalent to a p-value
of 0.05) were deemed significant.Real-time quantitative PCR
Selected biologically relevant differentially expressed genes
were analysed by quantitative PCR (qPCR). Extracted
RNA was reverse-transcribed to first strand cDNA using
Superscript III (Invitrogen, CA, USA). Sixteen primer
pairs were designed using Primer 3 (http://primer3.wi.mit.
edu/) and obtained from Integrated DNA Technologies,
(USA). Primer sequences are described in Additional file
6: Table S7. qPCR was performed using SYBR green
mastermix (Roche, Switzerland) on a Roche Lightcycler
480. The qPCR validation included animals from the
same RNA used in the microarray analysis. Results were
normalised to the housekeeping genes Hypoxanthine
phosphoribosyltransferase 1 (Hprt) and Peptidylprolyl
isomerase A (Ppia) using the 2-ΔΔCT method [94].
These genes have consistently remained stable across
numerous studies in the hippocampus eg [95,96]. Sig-
nificance was assessed using Student’s t-tests with the
criterion set at p < 0.05 and 1.2 fold change.Availability of supporting data
The data sets supporting the results of this article will
be available in the ArrayExpress repository, accession
number pending.
Additional files
Additional file 1: Figure S1. Neuroprotective effects of sAPPα are
concentration dependent. Change in cell death in DG/ob following
treatment of sAPPα (0.03-10 nM) relative to control/NMDA treatment.
*:p < 0.05, n = 4 animals, 19 slices/group. sAPPα neuroprotection followed
a U-shaped dose–response curve, with increasing concentrations of
sAPPα (to a maximum of 1 nM) leading to a significant neuroprotective
effect, which then decreased with increasing concentrations of sAPPα.
This agrees with our previous study [16], where we observed a dose
dependent facilitation of in vivo LTP by sAPPα, with little effects on LTP at
low concentrations, facilitation at mid-range concentrations and
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occupancy/binding properties of the receptor of sAPPα, as yet
unidentified [12,97]. No significant effects were detected following
incubation with the other sAPPα + NMDA concentrations.
Additional file 2: Tables S1-S4. Significantly expressed transcripts
clusters following 15 min (Table S1), 2 h (Table S2) and 24 h (Table S3)
sAPPα exposure. Table S4: Validation of selected differentially expressed
genes by qPCR including associated p-values. Entries without gene
symbols and titles have no annotations associated with these probe ids.
Additional file 3: Table S5. Expression of sAPPα related genes across
time. Overlapping temporal gene expression lists from Venn diagram
(Figure 2B). NC: no change in gene expression at this time.
Additional file 4: Table S6. DAVID functional annotation clustering of
sAPPα-regulated genes.
Additional file 5: Figure S2. Genes with annotations related to
neurogenesis and development. Associations between the 24 h gene list
and their annotations following DAVID functional analysis. The region in
green illustrates that all annotations are common across the cluster.
Enrichment score 2.35.
Additional file 6: Table S7. List of primers used for real-time qPCR.
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